Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 2/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | GAK | O14976 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | ULK1 | O75385 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5482665 | 0.88 | METAP1 (0.49) | METAP1ABCG2PTK2SYKAPP | |
| SCHEMBL4479894 | 0.72 | METAP1 (0.78) | METAP1KDM4EMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL5486938 | 0.72 | METAP1 (0.50) | METAP1KDM4ELMNASMN1; SMN2TGFBR1 | |
| SCHEMBL1416923 | 0.70 | KDM4E (0.56) | ABCG2KDM4EMAPK1SMN1; SMN2HSD17B10 | |
| SCHEMBL22864100 | 0.68 | GAK (0.61) | ABCG2GAKKDM4ELMNAMAPK1 | |
| SCHEMBL6452318 | 0.68 | NPC1 (0.64) | KDM4ELMNAMAPK1SMN1; SMN2HSD17B10 | |
| SCHEMBL6454205 | 0.67 | NR1H2 (0.56) | ABCG2KDM4ESMN1; SMN2 | |
| SCHEMBL30306474 | 0.67 | BRD4 (0.54) | ABCG2SYKKDM4ELMNAMAPK1 | |
| SCHEMBL265007 | 0.67 | BRD4 (0.54) | ABCG2SYKKDM4ELMNAMAPK1 | |
| SCHEMBL5482669 | 0.67 | POLB (0.47) | ABCG2PTK2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226927-B2 | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-7226927-B2 | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1351691-A4 | SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040097503-A1 | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2004-05-20 | — | — | US | disclosed |
| US-6716851-B2 | ANTICANCER AGENTS | CYTOVIA, INC. | 2004-04-06 | — | — | US | disclosed |
| EP-1351691-A1 | SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20030069239-A1 | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2002047690-A1 | SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069239-A1 | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof | API5, CASP2, APAF1 | METAP1 530/4885ABCG2 3307/4885ABCB1 1421/4885 |
| US-20040097503-A1 | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof | API5, CASP2, APAF1 | METAP1 450/4885ABCG2 3290/4885ABCB1 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.